Unaudited NAV for November 2023

Arix Bioscience PLC (ARIX) Unaudited NAV for November 2023 13-Dec-2023 / 07:00 GMT/BST Arix Bioscience plc Unaudited NAV for November 2023 LONDON, 13 December 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 30 November 2023 as follows: Date NAV Breakdown Total NAV NAV per share Listed Portfolio Unlisted Portfolio Cash Other Interests 30 November 2023 (unaudited) £54.3m £66.4m £105.8m £2.6m £229.1m £1.77 [ENDS] Enquiries For more information on Arix, please contact: Arix Bioscience plc [phone] [e-mail] Powerscourt Sarah MacLeod, Nick Johnson, Molly Ring [phone] [e-mail] About Arix Bioscience plc Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

ISIN:	GB00BD045071
Category Code:	MSCM
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	291541
EQS News ID:	1795525

End of Announcement	EQS News Service